黄芩苷及黄芩素治疗纤维化疾病探究进展.docVIP

黄芩苷及黄芩素治疗纤维化疾病探究进展 　　[摘要] 世界范围内，组织器官纤维化是许多疾病致残、致死的主要原因，目前尚没有能够阻止、逆转纤维化病变的药物，因此寻找和研发抗纤维化药物具有重大意义。组织器官纤维化病变是与细胞外基质过度沉积相关的非生理性瘢痕形成过程，可导致组织器官功能障碍，所有器官的纤维化病变具有相似的组织学异常改变。近年来，大量研究表明黄芩苷和黄芩素具有抑制多组织器官纤维化的作用，该文就黄芩苷和黄芩素在抗不同器官纤维化的作用和作用机制进行了综述。黄芩苷及其苷元黄芩素结构和药理作用相似，在体内存在广泛的生物转化作用，研究表明，黄芩苷和黄芩素能够通过抑制促纤维因子表达、抑制纤维化相信号通路、抗炎、抗氧化等多种机制抑制不同组织器官纤维化的发生和发展，是一种具有开发潜力的多组织器官抗纤维化药物。但目前关于黄芩苷和黄芩素抗纤维化研究也存在一些问题，作为非常有希望的潜在抗多器官组织纤维化药物，黄芩苷和黄芩素的抗纤维化研究有待于进一步加强 [关键词] 黄芩苷； 黄芩素； 抗纤维化； 器官纤维化 Research advances on baicalin and baicalein as potential therapeutic agents for fibrotic disease ZHU Qingjun （School of Traditional Chinese Medicine， Shandong University of Traditional Chinese Medicine， Ji′nan 250355， China） [Abstract] Tissue and organ fibrosis is the major cause for disability and death related to a variety of diseases worldwide. As specific therapies to halt， or even to reverse the existing tissue fibrosis are not yet available， it is of great significance to find new antifibrosis therapeutic agents. Tissue and organ fibrosis is a nonphysiological scarring process， associated with excessive deposition of extracellular matrix， and leads to impairment of organ function. Fibrotic lesions of all organs show similar histological abnormalities. In recent years， plenty of studies showed that Baicalin and baicalein had antifibrosis effects in different tissues or organs. In this paper， the effects and mechanisms of baicalin and baicalein on different organ fibrosis were reviewed. Baicalin and its aglycone baicalein had similarity in structural and pharmacological characteristics， with broad biotransformation effect within the body. The research suggested that baicalin and baicalein can suppress different tissue and organ fibrosis occurrence and development via various mechanisms， including downregulating expression of promotefibrosis cytokines， inhibiting profibrogenic signaling pathways， antiinflammatory and antioxidant effects. Though baicalin and baicalein are promising antifibrosis agents，